Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | ESRRA | P11474 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | P4HB | P07237 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16761889 | 0.87 | NOTUM (0.67) | NOTUMMAPTCYP3A4ESRRAKMT2A | |
| SCHEMBL5027170 | 0.85 | MAPT (0.58) | NOTUMMAPTCYP3A4KMT2AMEN1 | |
| SCHEMBL29638900 | 0.85 | ALDH1A1 (0.50) | NOTUMMAPTCYP3A4KMT2AMEN1 | |
| SCHEMBL615379 | 0.85 | CA12 (0.62) | MRGPRX4CA1CA2CA12CA7 | |
| SCHEMBL79042 | 0.85 | ALDH1A1 (0.50) | NOTUMMAPTCYP3A4KMT2AMEN1 | |
| SCHEMBL24860963 | 0.84 | NOTUM (0.60) | NOTUMMAPTCYP3A4ESRRAKMT2A | |
| SCHEMBL10088909 | 0.84 | NOTUM (0.56) | NOTUMMAPTCYP3A4ESRRAKMT2A | |
| SCHEMBL26291340 | 0.84 | NOTUM (0.56) | NOTUMMAPTCYP3A4ESRRAKMT2A | |
| SCHEMBL2018525 | 0.84 | NOTUM (0.56) | NOTUMMAPTCYP3A4ESRRAKMT2A | |
| SCHEMBL14776123 | 0.84 | HSD17B2 (0.60) | NOTUMMAPTCYP3A4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584726-B2 | Amino alcohol derivative, pharmaceutical composition and application thereof | BEIJING FORELAND PHARMA CO., LTD. (CN) | 2023-02-21 | — | — | US | disclosed |
| US-20210347745-A1 | AMINO ALCOHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | BEIJING FORELAND PHARMA CO., LTD. (CN) | 2021-11-11 | — | — | US | disclosed |
| EP-3647309-A1 | AMINO ALCOHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Beijing Foreland Pharma Co., Ltd. (CN) | 2020-05-06 | — | — | EP | disclosed |
| EP-2447240-B1 | Copper-catalysed Process for the Production of Substituted or Unsubstituted Trifluormethylated Aryl and Heteroaryl Compounds | SALTIGO GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8530666-B2 | Copper-catalysed process for the production of substituted or unsubstituted trifluormethylated aryl and heteroaryl compounds | SALTIGO GMBH (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530666-B2 | Copper-catalysed process for the production of substituted or unsubstituted trifluormethylated aryl and heteroaryl compounds | SALTIGO GMBH (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120245360-A1 | Copper-catalysed Process for the Production of Substituted or Unsubstituted Trifluormethylated Aryl and Heteroaryl Compounds | SALTIGO GMBH (DE) | 2012-09-27 | — | — | US | disclosed |
| US-20120245360-A1 | Copper-catalysed Process for the Production of Substituted or Unsubstituted Trifluormethylated Aryl and Heteroaryl Compounds | SALTIGO GMBH (DE) | 2012-09-27 | — | — | US | disclosed |
| EP-2447240-A1 | Copper-catalysed Process for the Production of Substituted or Unsubstituted Trifluormethylated Aryl and Heteroaryl Compounds | Saltigo GmbH (DE) | 2012-05-02 | — | — | EP | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| EP-2370431-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | Almirall S.A. (ES) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| US-7514452-B2 | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD (JP) | 2009-04-07 | — | — | US | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1489077-A1 | 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-6022899-A | EFFECTIVE INHIBITORS OF THE CELLULAR SODIUM PROTON ANTIPORTER | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-02-08 | — | — | US | disclosed |
| US-5753710-A | INHIBITORS OF THE CELLULAR SODIUM PROTON ANTIPORTER | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | NOTUM 4067/4885MAPT 3569/4885CYP3A4 1825/4885 |
| US-20210347745-A1 | AMINO ALCOHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | SSB, HLA-DRB1, LCP2 | NOTUM 2499/4885MAPT 42/4885CYP3A4 848/4885 |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | GLP1R, GCGR, GPR119 | NOTUM 2301/4885MAPT 4833/4885CYP3A4 517/4885 |
| US-11584726-B2 | Amino alcohol derivative, pharmaceutical composition and application thereof | SSB, HLA-DRB1, LCP2 | NOTUM 2499/4885MAPT 42/4885CYP3A4 848/4885 |
| US-20120245360-A1 | Copper-catalysed Process for the Production of Substituted or Unsubstituted Trifluormethylated Aryl and Heteroaryl Compounds | AOC3, AOC2, SOD1 | NOTUM 643/4885MAPT 3157/4885CYP3A4 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.